• Earlier in September 2025, GE HealthCare Technologies confirmed it is considering selling a stake in its China unit, and separately, the company announced regulatory clearances and US rollout plans for its latest AI-powered ultrasound systems and a nationwide cardiac imaging agent distribution agreement via CardioNavix.
• These moves underscore GE HealthCare’s shift toward expanding its addressable markets and leveraging advanced diagnostic technologies across both international and outpatient settings.
• We’ll now consider how the potential China unit stake sale could recalibrate GE HealthCare’s investment narrative and long-term market positioning.

AI is about to change healthcare. These 31 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

GE HealthCare Technologies Investment Narrative Recap

To be a shareholder in GE HealthCare Technologies, you generally need to believe in its ability to expand leadership in diagnostic imaging and advanced healthcare solutions while managing exposure to global markets, especially China. While news that the company may sell a stake in its China unit is getting attention, this development does not materially shift the importance of near-term growth catalysts like new product launches, but it does add a layer of uncertainty around regulatory and tariff risks affecting the business.

Among recent announcements, the US-wide rollout of Flyrcado™, an AI-enhanced cardiac PET imaging agent in partnership with CardioNavix, is especially relevant. This rollout supports one of GE HealthCare’s central growth drivers: expanding recurring revenues through pharmaceutical diagnostics and digital solutions, regardless of potential operational adjustments elsewhere. Contrasting this progress, investors should also remain alert to the ongoing risk that US-China tariffs could still impact earnings and margins in ways that ...

GE HealthCare Technologies' outlook anticipates $22.7 billion in revenue and $2.5 billion in earnings by 2028. This projection requires 4.3% annual revenue growth and a $0.3 billion increase in earnings from the current $2.2 billion.

Uncover how GE HealthCare Technologies' forecasts yield a $88.00 fair value, a 17% upside to its current price.

Exploring Other Perspectives

Personal fair value estimates from four Simply Wall St Community members range from US$62.11 to US$123.53. With exposure to China under review, you may see even greater variations in opinions, making it valuable to view multiple angles before making decisions.

Explore 4 other fair value estimates on GE HealthCare Technologies - why the stock might be worth 17% less than the current price!

Build Your Own GE HealthCare Technologies Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your GE HealthCare Technologies research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision.
• Our free GE HealthCare Technologies research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate GE HealthCare Technologies' overall financial health at a glance.

Searching For A Fresh Perspective?

Our top stock finds are flying under the radar-for now. Get in early:

• We've found 19 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.
• Find companies with promising cash flow potential yet trading below their fair value.
• Trump has pledged to "unleash" American oil and gas and these 22 US stocks have developments that are poised to benefit.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.